Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival …
Biohaven’s migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and …
Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie—thanks to Nurtec ODT’s dual acute-plus-prevention nod and an aggressive digital-first strategy. Digital ads across …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
